Anselm A Derda1, Sabrina Thum1, Johan M Lorenzen1, Udo Bavendiek2, Joerg Heineke2, Britta Keyser3, Manfred Stuhrmann3, Raymond C Givens4, Peter J Kennel4, P Christian Schulze4, Julian D Widder2, Johann Bauersachs2, Thomas Thum5. 1. Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Hannover, Germany. 2. Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany. 3. Institute for Human Genetics, Hannover Medical School, Hannover, Germany. 4. Division of Cardiology, Columbia University Medical Center, New York, NY, 10032. 5. Institute of Molecular and Translational Therapeutic Strategies (IMTTS), IFB-Tx, Hannover Medical School, Hannover, Germany; Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; National Heart and Lung Institute, Imperial College London, UK. Electronic address: thum.thomas@mh-hannover.de.
Abstract
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is caused by mutations in different structural genes and induces pathological hypertrophy with sudden cardiac death as a possible consequence. HCM can be separated into hypertrophic non-obstructive and obstructive cardiomyopathy (HNCM/HOCM) with different clinical treatment approaches. We here distinguished between HNCM, HOCM, cardiac amyloidosis and aortic stenosis by using microRNA profiling and investigated potential interactions between circulating miRNA levels and the most common mutations in MYH7and MYBPC3 genes. METHODS: Our study included 4 different groups: 23 patients with HNCM, 28 patients with HOCM, 47 patients with aortic stenosis and 22 healthy controls. Based on previous findings, 8 different cardiovascular known microRNAs (miR-1, miR-21, miR-29a, miR-29b, miR-29c, miR-133a, miR-155 and miR-499) were studied in serum of all patients and compared with clinically available patient data. RESULTS: We found miR-29a levels to be increased in patients with HOCM and correlating markers of cardiac hypertrophy. This was not the case in HNCM patients. In contrast, we identified miR-29c to be upregulated in aortic stenosis but not the other patient groups. ROC curve analysis of miR-29a/c distinguished between HOCM patients and aortic stenosis patients. MiR-29a and miR-155 levels discriminated HNCM patients from patients with senile cardiac amyloidosis. MiR-29a increased mainly in HOCM patients with a mutation in MYH7, whereas miR-155 was decreased in hypertrophic cardiomyopathy patients with a mutation in MYBPC3. CONCLUSION: We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
BACKGROUND:Hypertrophic cardiomyopathy (HCM) is caused by mutations in different structural genes and induces pathological hypertrophy with sudden cardiac death as a possible consequence. HCM can be separated into hypertrophic non-obstructive and obstructive cardiomyopathy (HNCM/HOCM) with different clinical treatment approaches. We here distinguished between HNCM, HOCM, cardiac amyloidosis and aortic stenosis by using microRNA profiling and investigated potential interactions between circulating miRNA levels and the most common mutations in MYH7and MYBPC3 genes. METHODS: Our study included 4 different groups: 23 patients with HNCM, 28 patients with HOCM, 47 patients with aortic stenosis and 22 healthy controls. Based on previous findings, 8 different cardiovascular known microRNAs (miR-1, miR-21, miR-29a, miR-29b, miR-29c, miR-133a, miR-155 and miR-499) were studied in serum of all patients and compared with clinically available patient data. RESULTS: We found miR-29a levels to be increased in patients with HOCM and correlating markers of cardiac hypertrophy. This was not the case in HNCM patients. In contrast, we identified miR-29c to be upregulated in aortic stenosis but not the other patient groups. ROC curve analysis of miR-29a/c distinguished between HOCM patients and aortic stenosispatients. MiR-29a and miR-155 levels discriminated HNCM patients from patients with senile cardiac amyloidosis. MiR-29a increased mainly in HOCM patients with a mutation in MYH7, whereas miR-155 was decreased in hypertrophic cardiomyopathypatients with a mutation in MYBPC3. CONCLUSION: We demonstrated that miR-29a and miR-29c show a specific signature to distinguish between aortic stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could be developed into clinically useful biomarkers.
Authors: Roberta Roncarati; Chiara Viviani Anselmi; Maria Angela Losi; Laura Papa; Elena Cavarretta; Paula Da Costa Martins; Carla Contaldi; Gloria Saccani Jotti; Anna Franzone; Laura Galastri; Michael V G Latronico; Massimo Imbriaco; Giovanni Esposito; Leon De Windt; Sandro Betocchi; Gianluigi Condorelli Journal: J Am Coll Cardiol Date: 2013-10-23 Impact factor: 24.094
Authors: Christophe Bauters; Regalla Kumarswamy; Angelika Holzmann; Julia Bretthauer; Stefan D Anker; Florence Pinet; Thomas Thum Journal: Int J Cardiol Date: 2013-01-22 Impact factor: 4.164
Authors: Christian Widera; Shashi K Gupta; Johan M Lorenzen; Claudia Bang; Johann Bauersachs; Kerstin Bethmann; Tibor Kempf; Kai C Wollert; Thomas Thum Journal: J Mol Cell Cardiol Date: 2011-07-23 Impact factor: 5.000
Authors: Milosz Jaguszewski; Julia Osipova; Jelena-Rima Ghadri; Lars Christian Napp; Christian Widera; Jennifer Franke; Marcin Fijalkowski; Radoslaw Nowak; Marta Fijalkowska; Ingo Volkmann; Hugo A Katus; Kai C Wollert; Johann Bauersachs; Paul Erne; Thomas F Lüscher; Thomas Thum; Christian Templin Journal: Eur Heart J Date: 2013-09-17 Impact factor: 29.983
Authors: Udit Agarwal; Alex George; Srishti Bhutani; Shohini Ghosh-Choudhary; Joshua T Maxwell; Milton E Brown; Yash Mehta; Manu O Platt; Yaxuan Liang; Susmita Sahoo; Michael E Davis Journal: Circ Res Date: 2016-11-21 Impact factor: 17.367